Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

M. Wirth, C. Tyrrell, K. Delaere, M. Sánchez-Chapado, J. Ramon, D. M.A. Wallace, J. Hetherington, F. Pina, C. F. Heyns, S. Navani, J. Armstrong

Research output: Contribution to journalArticlepeer-review

Abstract

Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalProstate Cancer and Prostatic Diseases
Volume10
Issue number1
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Dive into the research topics of 'Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up'. Together they form a unique fingerprint.

Cite this